Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Regeneron Pharmaceuticals Suffers Worst Month in Two Years After Legal Setback
Regeneron Pharmaceuticals shares dropped 12% in September due to a court ruling allowing Amgen to potentially launch a biosimilar of Eylea early, creating uncertainty for Regeneron's US Eylea franchise. Despite this, analysts remain bullish on Regeneron, with growth expected from other drugs like Dupixent offsetting potential losses.
FDA approves dupilumab for COPD with type 2 inflammation
FDA approves dupilumab for treating poorly controlled COPD with type 2 inflammation, based on BOREAS and NOTUS studies showing reduced exacerbation rates and improved lung function.
FDA Approves Dupilumab as Add-On Maintenance Therapy For Adults With COPD
FDA approves dupilumab (Dupixent) as add-on therapy for adult COPD patients with eosinophilic phenotype, based on phase 3 trials BOREAS and NOTUS showing significant reduction in exacerbations, improved lung function, and quality of life. Dupilumab, a monoclonal antibody targeting IL-4 and IL-13 pathways, also approved for pediatric eosinophilic esophagitis and has multiple other indications.
Related Clinical Trials:
Sanofi Blockbuster Drug Wins Clearance in US for Lung Disease
Sanofi's Dupixent approved by US FDA for COPD, following EU approval, marking a decade's first new treatment approach for the disease. The drug, co-developed with Regeneron, is expected to generate €21 billion annually by 2030 before facing patent expirations.
FDA Approves Dupilumab as First Biologic Treatment for COPD
The FDA approved dupilumab (Dupixent) as the first biologic treatment for uncontrolled COPD with an eosinophilic phenotype, based on phase 3 trials showing reduced exacerbations and improved lung function.
Related Clinical Trials:
Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
FDA approves Dupixent for inadequately controlled COPD with eosinophilic phenotype, based on phase 3 studies showing significant reduction in exacerbations, improved lung function, and health-related quality of life.
FDA, after delay, clears Regeneron and Sanofi drug for COPD
FDA approves Dupixent for COPD, making it the first biologic medicine for the condition in the U.S. This expansion is expected to boost sales, which reached almost $12 billion globally last year. Dupixent targets Type 2 inflammation in a subset of COPD patients, showing reduced exacerbations and improved lung function in trials. European regulators approved Dupixent for COPD in July, but U.S. approval required additional efficacy data. The approval comes as Regeneron faces market value loss due to a court case, increasing pressure on its pipeline.
FDA Approves Dupilumab (Dupixent) for Treatment of COPD
FDA approves dupilumab (Dupixent) for COPD, based on BOREAS and NOTUS trials, offering reduced exacerbations and improved lung function in patients with type 2 inflammation.
Dupixent approved in the US as the first-ever biologic medicine for patients
Dupixent approved by FDA as first biologic for COPD patients with eosinophilic phenotype, showing significant reduction in exacerbations and improvements in lung function and quality of life in phase 3 studies.
© Copyright 2025. All Rights Reserved by MedPath